Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  immunological adjuvant OPT-821
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-5 of 5 for your search:
Start Over
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: GOG-0255, NCI-2009-01176, CDR0000636384, U10CA027469, NCT00857545
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MV-0109DP001, NCT01141491
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OPT-822-001, NCT01516307
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-099, NCT01223235
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid
Phase: No phase specified
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 08-095, NCT01349647
Start Over